Roche releases Q3 results; Tamiflu drops 60 percent

BASEL, Switzerland Roche has released its third quarter financials and its oncology drugs Avastin and Herceptin are performing strongly, making up for the 60 percent drop in sales of Tamiflu.

The company’s pharmacy division had quarterly sales of over $7.5 billion. Tamiflu sales went down to almost $220 million this quarter from almost $570 million during the third quarter in 2006.

Herceptin and Avastin saw increases of 26 and 41 percent, respectively, compared to the same time last year.